Envafolimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Envafolimab
- anti pd l1 monoclonal antibody kn035
- ANTI-PD-L1 MONOCLONAL ANTIBODY KN035
- asc 22
- ASC-22
- asc22
- Asc22
- ASC22
- envafolimab
- Envafolimab
- envafolimab [INN]
- Envafolimab [WHO-DD]
- Envafolimab Injection
- envafolimab inn
- envafolimab who dd
- immunoglobulin g anti human programmed death ligand 1 human camelidae monoclonal kn 035 gamma chain variable region fragment fusion protein with immunoglobulin g1 human monoclonal kn 035 gamma 1 chain fc fragment dimer
- IMMUNOGLOBULIN G, ANTI-(HUMAN PROGRAMMED DEATH LIGAND 1) (HUMAN-CAMELIDAE MONOCLONAL KN-035 .GAMMA.-CHAIN VARIABLE REGION FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN MONOCLONAL KN-035 .GAMMA.1-CHAIN FC FRAGMENT), DIMER
- immunoglobulin vh h ch2 ch3 gamma1 chain dimer anti homo sapiens cd274 programmed death ligand 1 pdl1 pd l1 b7 homolog 1 b7h1 monoclonal antibodygamma1 heavy chain vh h ch2 ch3 1 360 vh vicugna pacos ighv3 3 01 80 6 ighd ighj5 01 92 3 homo sapiens ighv3 64 04 78 4 ighd ighj1 01 92 3 8 8 21 1 128 homo sapiens ighg1 01 g1m1 hinge 1 15 c5 s 133 129 143 ch2 144 253 d27 a 178 p116 g 244 ch3 d12 269 l14 271 254 358 chs 359 360 129 360 dimer 139 139 142 142 bisdisulfide
- IMMUNOGLOBULIN VH-H-CH2-CH3 GAMMA1 CHAIN DIMER, ANTI-(HOMO SAPIENS CD274 (PROGRAMMED DEATH LIGAND 1, PDL1, PD-L1, B7 HOMOLOG 1, B7H1)), MONOCLONAL ANTIBODYGAMMA1 HEAVY CHAIN VH-H-CH2-CH3 (1-360) (VH (VICUGNA PACOS IGHV3-3*01 (80.6%)-(IGHD)-IGHJ5*01 (92.3%)/HOMO SAPIENS IGHV3-64*04 (78.4%)-(IGHD)-IGHJ1*01 (92.3%)) (8.8.21) (1-128)-HOMO SAPIENS IGHG1*01 G1M1 (HINGE 1-15, C5>S (133) (129-143), CH2 (144-253) D27>A (178), P116>G (244), CH3 D12 (269) L14 (271) (254-358), CHS (359-360)) (129-360))DIMER (139-139'':142-142'')-BISDISULFIDE
- kn 035
- Kn 035
- KN-035
- kn035
- Kn035
- KN035
- CAS registry numbers
- 2102192-68-5
- ChEMBL ID
- CHEMBL4298006
- FDA ingredient codes (UNII)
- ES1M06M6QH
- Patents
- 0
- Designations
- 2
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- envafolimab
- Type
- Antibody
- Drug name stem
- -mab
- Approval recorded by Guide to Pharmacology
- Yes
- Mechanism
- Programmed cell death 1 ligand 1 binding agent
- Action type
- BINDING_AGENT
- Target
- Programmed cell death 1 ligand 1
- Protein identifier
- Q9NZQ7
- Action
- Binding
- Action type
- Binding
- Target
- programmed cell death 1 ligand 1
- Gene symbol
- programmed cell death 1 ligand 1
- Median affinity
- 8.52
- Affinity units
- pKd
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Programmed cell death 1 ligand 1 binding agent
- Action type
- BINDING AGENT
- Target
- Programmed cell death 1 ligand 1
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Sarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Biliary Tract Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003891
- Subject identifier
- D001661
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004142
- Subject identifier
- D015179
- Condition
- Hepatitis B, Chronic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004239
- Subject identifier
- D019694
- Condition
- Nasopharyngeal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004252
- Subject identifier
- D009303
- Condition
- Colonic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004288
- Subject identifier
- D003110
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005922
- Subject identifier
- D004938
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000359
- Subject identifier
- D010190
- Condition
- Rectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000657
- Subject identifier
- D012004
- Condition
- Meningeal Carcinomatosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001012
- Subject identifier
- D055756
- Condition
- Sarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001968
- Subject identifier
- D012509
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002974
- Subject identifier
- D002583
- Condition
- Biliary Tract Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0003060
- Subject identifier
- D001661
- Condition
- Adenocarcinoma
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0003219
- Subject identifier
- D000230
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Gallbladder Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005411
- Subject identifier
- D005706
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007576
- Subject identifier
- D004938
And 5 more, listed on the interactive page.
- Condition identifier
- EFO_0000180
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001075
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004142
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004239
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000657
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001012
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001961
- Condition identifier
- EFO_1001968
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000544
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002142
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002158
- Condition identifier
- MONDO_0002169
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003060
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003060
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003210
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005005
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005008
- Highest recorded phase
- 2
And 30 more, listed on the interactive page.
- Event
- alanine aminotransferase increased
- Reports
- 2
- Reporting signal score
- 6.13248
- Event
- anaemia
- Reports
- 5
- Reporting signal score
- 16.9242
- Event
- aspartate aminotransferase increased
- Reports
- 2
- Reporting signal score
- 6.37947
- Event
- biliary tract disorder
- Reports
- 1
- Reporting signal score
- 6.40325
- Event
- decreased appetite
- Reports
- 3
- Reporting signal score
- 8.99762
- Event
- endocrine disorder
- Reports
- 1
- Reporting signal score
- 6.78159
- Event
- fatigue
- Reports
- 5
- Reporting signal score
- 12.3454
- Event
- gastrointestinal disorder
- Reports
- 2
- Reporting signal score
- 6.98039
- Event
- hyperbilirubinaemia
- Reports
- 3
- Reporting signal score
- 16.3299
- Event
- hypertension
- Reports
- 4
- Reporting signal score
- 12.7799
- Event
- hyperthyroidism
- Reports
- 2
- Reporting signal score
- 9.57268
- Event
- hypoalbuminaemia
- Reports
- 4
- Reporting signal score
- 24.8646
- Event
- hypokalaemia
- Reports
- 2
- Reporting signal score
- 6.99414
- Event
- hypothyroidism
- Reports
- 3
- Reporting signal score
- 14.1504
- Event
- immune effector cell-associated neurotoxicity syndrome
- Reports
- 1
- Reporting signal score
- 6.30152
- Event
- leukopenia
- Reports
- 3
- Reporting signal score
- 11.4774
- Event
- myocardial necrosis marker increased
- Reports
- 1
- Reporting signal score
- 6.50483
- Event
- neutropenia
- Reports
- 4
- Reporting signal score
- 13.2694
- Event
- palmar-plantar erythrodysaesthesia syndrome
- Reports
- 3
- Reporting signal score
- 14.0171
- Event
- pneumonitis
- Reports
- 3
- Reporting signal score
- 14.0255
- Event
- post embolisation syndrome
- Reports
- 1
- Reporting signal score
- 8.67634
- Event
- rash
- Reports
- 5
- Reporting signal score
- 14.2373
- Event
- thrombocytopenia
- Reports
- 5
- Reporting signal score
- 18.9049
- Event
- transaminases increased
- Reports
- 2
- Reporting signal score
- 7.89095
- Event
- vomiting
- Reports
- 4
- Reporting signal score
- 9.64434
- NCT02827968
- NCT03101488
- NCT03248843
- NCT03667170
- NCT04182789
- NCT04891198
- NCT06301828
- NCT06470971
- NCT04034823
- NCT04465890
- NCT04910386
- NCT05055167
- NCT05068427
- NCT05243355
- NCT05360979
- NCT05414630
- NCT05465733
- NCT05529355
- NCT05534113
- NCT05910034
- NCT06108726
- NCT05112991
- NCT05129189
- NCT05203276
- NCT05904015
And 29 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (84)
- 89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors
- A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC
- A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)
- A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread
- A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
- A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients
- A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
- A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
- A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer
- A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer
- A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
- Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
- ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection
- Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
- Clinical Experience and Real-world Safety and Effectiveness of Envafolimab: Patient Access Program
- Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
- Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
- D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
- Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer
- Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma
In development for (28)
- Biliary tract cancer Phase 2
- Biliary tract neoplasm Phase 2
- Breast cancer Phase 2
- Cancer Phase 2
- Cervical cancer Phase 2
- Chronic hepatitis B virus infection Phase 2
- Colonic neoplasm Phase 2
- Colorectal cancer Phase 2
- Colorectal neoplasm Phase 2
- Endometrial cancer Phase 2
- Esophageal cancer Phase 2
- Esophageal squamous cell carcinoma Phase 2
- Gallbladder cancer Phase 2
- Gastric adenocarcinoma Phase 2
- Gastroesophageal junction adenocarcinoma Phase 2
- Hepatocellular carcinoma Phase 2
- HIV infectious disease Phase 2
- Lung neoplasm Phase 2
- Malignant colon neoplasm Phase 2
- Malignant pancreatic neoplasm Phase 2
Other linked conditions (3)
- Intrahepatic cholangiocarcinoma
- Malignant epithelial tumor of ovary
- Ovarian carcinoma
Targets (1)
- CD274 Programmed cell death 1 ligand 1 binding agent